Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $60.00 price objective on the stock. A number of other analysts have also commented on APLS. Oppenheimer reissued an outperform rating on shares […]

Related Keywords

Canada ,Pascal Deschatelets ,Alec Machiels ,Apellis Pharmaceuticals Inc ,National Bank ,Needham Company ,Wealth Management Inc ,Clearstead Advisors ,Wells Fargo Company ,Analyst Recommendations For Apellis Pharmaceuticals ,Apellis Pharmaceuticals ,Us Bancorp ,Apellis Pharmaceuticals Stock Performance ,News Ratings For Apellis Pharmaceuticals Daily ,Free Report ,Wells Fargo ,Moderate Buy ,Get Free Report ,Director Alec Machiels ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Reiterated Rating ,Needham Company Llc ,